Table 2.
IPN proven benign | IPN proven metastases | |
---|---|---|
Patients (n) | 73 | 27 |
Female | 39/73 | 4/27 |
Age, median (range) | 62 (24–85) | 56 (31–87) |
Stage I (%) | 4 | 0 |
Stage IIA (%) | 4 | 0 |
Stage IIB (%) | 10 | 4 |
Stage IIC (%) | 8 | 11 |
Stage III (%) | 74 | 85 |
IPN proven benign | IPN proven metastases | |
---|---|---|
Patients (n) | 73 | 27 |
Female | 39/73 | 4/27 |
Age, median (range) | 62 (24–85) | 56 (31–87) |
Stage I (%) | 4 | 0 |
Stage IIA (%) | 4 | 0 |
Stage IIB (%) | 10 | 4 |
Stage IIC (%) | 8 | 11 |
Stage III (%) | 74 | 85 |